What Is The Most Significant Difference Between Humalog And Lantus?

Insulin Lispro

Insulin Lispro. Insulin lispro, of recombinant DNA origin, is a human insulin analogue created by reversal of the amino acids at positions 28 and 29 on the human insulin B chain. Insulin lispro was the first insulin analogue to receive approval by the U.S. Food and Drug Administration. It is chemically Lys(B28),Pro(B29) insulin and is created in a special, nonpathogenic laboratory strain of Escherichia coli that has been genetically altered by the addition of the gene for insulin lispro. The effect of this amino acid rearrangement is to reduce the capacity of the insulin to self-aggregate in subcutaneous tissues, resulting in behavior similar to that of monomeric insulin. This leads to lispro's more rapid absorption and shorter duration of action compared with regular insulin when given by subcutaneous injection. However, lispro is not intrinsically more active and on a molar basis is equipotent to human insulin. When they are given by intravenous injection, the pharmacokinetic profiles of lispro and human regular insulin are similar. Because of its rapid onset of action (within 5 to 15 minutes after administration) and peak action within 1 to 2 hours, lispro was the first insulin to mimic the time course of the increase in plasma glucose seen after ingestion of a carbohydrate-rich meal. 6.19.6.5.3.1 Rapid-acting insulin analogs (lispro, aspart, and glulisine) Changes in the amino acid sequence of the insulin analogs lispro, aspart, and glulisine reduce the tendency to self-associate into hexamers, resulting in more rapid onset and a shorter duration of action compared to regular human insulin. Insulin lispro (Humalog) has a reversal of amino acid sequence at the B28 (proline) and B29 (lysine) positions, resulting in insulin lysine-proline. Insulin aspart (Novolog) has Continue reading >>

Lantus Versus Humalog Mix As Add-on Therapy In Type Diabetes Patients Failing Sulfonylurea And Metformin Combination Treatment

Study Primary Objectives: To compare glycemic control, as measured by hemoglobin A1c (A1C), between insulin glargine and 75% insulin lispro protamine suspension/25% insulin lispro as add-on therapies in subjects who failed oral combination therapy with sulfonylurea and metformin. Study Secondary Objectives : To compare the following measures between subjects receiving insulin glargine or 75% insulin lispro protamine suspension/25% insulin lispro: Incidence of hypoglycemia Change in weight Change in serum lipid profile Percentage of subjects achieving A1C levels ≤7% The planned duration of enrollment is 6 months. The study consists of 2 weeks screening phase and a study period that was planned to be 24 weeks. Study Type : Interventional (Clinical Trial) Actual Enrollment : 212 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Lantus® (Insulin Glargine[rDNA Origin] Injection) vs Humalog® Mix 75/25 (75% Insulin Lispro Protamine Suspension and 25% Insulin Lispro Injection) as add-on Therapy in Type 2 Diabetes Patients Failing Sulfonylurea and Glucophage (Metformin) Combination Treatment: a Randomized, Open, Parallel Study Study Start Date : July 2001 Primary Completion Date : December 2002 Study Completion Date : December 2002 Arm Intervention/treatment Experimental: Insulin glargine Lantus (insulin glargine) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by Self-monitoring blood glucose (SMBG). The starting dosage of m Continue reading >>

Humalog[reg] And Humalog Mix50[reg] Provide Better Glycemic Control Than Lantus[reg] In Patients With Type 2 Diabetes

Humalog[reg] and Humalog Mix50[reg] Provide Better Glycemic Control Than Lantus[reg] in Patients with Type 2 Diabetes Primary objective of this 6 mo Primary objective of this 6 months multicenter randomized prospective open-label parallel group study was to evaluate the effect of a therapy with 3x daily Humalog[reg] (HL) or Humalog Mix50[reg] (HM) versus 1x daily Lantus[reg] (L) on glycemic control. Primary efficacy criterion was the 2 h postprandial glucose excursion after breakfast at 6 months; secondary endpoints included HbA1c and frequency of hypoglycemic episodes. The primary analysis of the a priori arranged hypotheses (HL vs. L, HM vs. L) was conducted on the ITT population using MANN-WHITNEY-U-tests.[br]159 patients with type 2 diabetes were assigned to one of the 3 treatment arms: HL (n=52), HM (n=54), L (n=53). No relevant differences were observed between the groups regarding baseline characteristics (data shown as mean[plusmn]SD). Patients[rsquo] age was 59.4 ([plusmn]9.5) years, BMI 31.0 ([plusmn]4.5) kg/m[sup2], diabetes duration 5.5 ([plusmn]2.9) years. Most patients were previously treated with sulfonylureas and/or metformin. After 6 months treatment the HL and HM groups showed significantly lower blood glucose excursions after breakfast than the L group (p[lt]0.0001vs. HL, p=0.0006 vs. HM respectively). The HbA1c did not differ between groups at baseline (HL 8.3[plusmn]1.2%, HM and L 8.1[plusmn]1.2%). At Month 6, HbA1c had improved by 1.1% in the HL group, by 1.2% in the HM group and by 0.3% in the L-group. Differences between HL and HM groups vs. the L group were highly significant (p[le]0.001 for both). No relevant treatment group differences were observed with respect to the number of hypoglycemic events, although daily insulin dose at the end of t Continue reading >>

Winningham's Critical Thinking Cases In Nursing

You work in a diabetes mellitus (DM) treatment center located in a large teaching hospital. The first patient you meet is K.W., a 25-year-old Hispanic female, who was just released from the hospital 2 days ago after being diagnosed with type I DM. Nine days ago, K.W. went to see the physician after a 1-month history of frequent urination, thirst, severe fatigue, blurred vision, and some burning and tingling in her feet. She attributed those symptoms to working long hours at the computer. Her random glucose level was 410 mg/dL. The next day, her labs were as follows: fasting glucose 335 mg/dL, HbA1C 8.8%, cholesterol 310 mg/dL, triglycerides 300 mg/ dL, HDL 25 mg/dL, LDL 160 mg/dL, ratio 12.4, creatinine 0.9 mg/dL, and body mass index 37.6. Her BP is 160/96 mm Hg. She was admitted to the hospital for control of her glucose levels and the initiation of multi-dose injection insulin therapy with carbohydrate (CHO) counting. After discharge, K.W. has been referred to you for comprehensive education. You are to cover four basic areas: pharmacotherapy, glucose monitoring, medical nutrition therapy (MNT), and exercise. K.W. was started on sliding scale lispro (Humalog) four times daily and glargine (Lantus) insulin 30 units at bedtime. What is the most significant difference between these two insulins? You work in a diabetes mellitus (DM) treatment center located in a large teaching hospital. The first patient you meet is K.W., a 25-year-old Hispanic female, who was just released from the hospital 2 days ago after being diagnosed with type I DM. Nine days ago, K.W. went to see the physician after a 1-month history of frequent urination, thirst, severe fatigue, blurred vision, and some burning and tingling in her feet. She attributed those symptoms to working long hours at the c Continue reading >>

Lantus Vs. Humalog

font size A A A 1 2 3 Next Are Lantus and Humalog the Same Thing? Lantus (insulin glargine [rdna origin]) and Humalog (insulin lispro [rDNA origin]) are both forms of insulin used to treat type 1 (insulin-dependent) or type 2 (non insulin-dependent) diabetes. A difference is that Humalog is usually given together with another long-acting insulin. Humalog is also used together with oral medications to treat type 2 (non insulin-dependent) diabetes in adults. What Are Possible Side Effects of Lantus? The most common side effects of Lantus is hypoglycemia, or low blood sugar. Symptoms include: headache, hunger, weakness, sweating, tremors, irritability, trouble concentrating, rapid breathing, fast heartbeat, fainting, or seizure (severe hypoglycemia can be fatal). Other common side effects of Lantus include pain, redness, swelling, itching, or thickening of the skin at the injection site. These side effects usually go away after a few days or weeks. What Are Possible Side Effects of Humalog? Common side effects of Humalog include: injection site reactions (e.g., pain, redness, irritation). Low blood sugar (hypoglycemia), is the most common side effect of insulin lispro such as Humalog. Symptoms of low blood sugar may include headache, nausea, hunger, confusion, drowsiness, weakness, dizziness, blurred vision, fast heartbeat, sweating, tremor, trouble concentrating, confusions, or seizure (convulsions). Low blood potassium levels (hypokalemia). Symptoms include dry mouth, increased thirst, increased urination, uneven heartbeats, muscle pain or weakness, leg pain or discomfort, or confusion What is Lantus? Lantus is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 Continue reading >>

Lantus & Humalog - Diabetes - Diabetes Forums

Registration is fast, simple and absolutely free so please,join our community todayto contribute and support the site. This topic is now archived and is closed to further replies. Can I take my Lantus at the same time as my humalog? Which one should i take first? I try to take my Lantus everyday at the same time but i work shift work. How should i do my injections? Yes you can take them at the same time, but not in the same syringe or the same exact injection site. You would usually take the Humalog a little before (or same time) as eating carbs/meals, and/or to correct a high bg. Lantus is usually taken either in the morning or at bedtime (and sometimes split into 2 doses per day). I think I scanned another post about you taking Lantus already, but just getting the Humalog, correct? Do you have a ratio for how much Humalog to take for a certain amount of carbs? (example 1 unit for 15 carbs). And a ratio for how much Humalog to take to lower a high bg? (example 1 unit lowers bg 50 points). I have just taken my first dose of novolog (what is the difference between humolog and novolog by the way?) I was @ 120 mg/dl before I ate Cereal and Milk(usually makes me about 225 post prandial) and some pringles. 30 min after first bite I was at 170 mg/dl, 1hr after first bite I was 90 mg/dl , 67 mg/dl 1hr 40 min after first bite... bout to eat something so i dont get too low Most people say they are the same. But I found Novolog to be quicker and stronger than Humalog. It looks like you are finding the same thing. Well I just ate some meatloaf, mash potatoes, mixed vegies, cucumber and a cup of ice cream... no rapid insulin. I will see where that gets me. How long does the rapid stuff stay in the body, when does it peak? Generally speaking, most of it is finished in three hours, Continue reading >>

How Long Should Insulin Be Used Once A Vial Is Started?

Editor’s comment: The commentary by Dr. Grajower has such important clinical relevance that responses were invited from the three pharmaceutical companies that supply insulin in the U.S. and the American Diabetes Association, and all of these combined in this commentary. The commenting letter and individual responses were authored separately and are completely independent of each other. Diabetic patients treated with insulin, whether for type 1 or type 2 diabetes, are prone to often unexplained swings in their blood glucose. These swings can vary from dangerously low to persistently high levels. Most diabetic patients, and most physicians, will adjust insulin regimens so as to avoid hypoglycemia at the expense of hyperglycemia. Among the “textbook” reasons for variable glucose responses to any given insulin regimen are 1) site of administration, 2) exercise, 3) bottles not adequately mixed before drawing the insulin (for NPH, Lente, or Ultralente), and 4) duration of treatment with insulin (1). A new insulin was marketed by Aventis Pharmaceuticals about 1 year ago, insulin glargine (Lantus). The manufacturer seemed to stress that patients not use a started bottle of this insulin for >28 days (2). Two patients of mine highlighted this point. L.K. is a 76-year-old woman with type 2 diabetes, diagnosed at 55 years of age, and treated with insulin since age 56. Her insulin regimen was changed to Lantus at night together with Novolog before meals. She monitors her blood glucose four times a day. She used a bottle of Lantus until it ran out; therefore, a bottle lasted for 2 months. Her recent HbA1c was 7.6%. I retrospectively analyzed her home glucose readings by averaging her fasting blood glucose levels for the first 15 days of a new bottle and the last 15 days of tha Continue reading >>

Insulin Pens: Improving Adherence And Reducing Costs

The advantages offered by insulin pens may help improve patient adherence. Currently 8.3% of the United States adult population, or 25.8 million people, have diabetes. Of these cases, more than 90% are cases of type 2 diabetes mellitus (T2DM) and at least 1 million are estimated to be cases of type 1 diabetes mellitus (T1DM). Although a variety of oral medications are available for patients with diabetes, insulins remain an important component of treatment.1,2 Insulins are the standard therapy in patients with T1DM and are ultimately used in patients with T2DM who do not respond adequately to other treatment modalities. Although in some settings insulins may be administered intravenously (eg, with an insulin pump), the vast majority of insulin administrations are subcutaneous injections.1,2 Available Forms and Administration In the United States, 2 types of insulins are available: recombinant human insulins and insulin analogs. Recombinant human insulin is available from 2 manufacturers (Humulin by Eli Lilly and Novolin by Novo Nordisk); each of these is available in a regular form and in a longer-acting neutral protamine hagedorn (NPH) form. Unlike recombinant human insulins, insulin analogs are structurally modified forms of insulin that are designed to either lower blood sugar rapidly or maintain low blood sugar levels over time. These insulin analogs may be classified as rapid-acting and long-acting insulins. Rapid-acting insulins include insulin lispro, insulin aspart, and insulin glulisine, and long-acting insulins include insulin glargine and insulin detemir. Premixed formulations of insulin are also available.1,2 Regardless of the differences between insulin formulations, all conventional types of insulin can be administered subcutaneously. Subcutaneous injectio Continue reading >>

Insulin Glargine

Insulin glargine, marketed under the names Lantus, among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert). Pharmacokinetically, it resembles basal insulin secretion of non-diabetic pancreatic beta cells. Sometimes, in type 2 diabetes and in combination with a short acting sulfonylurea (drugs which stimulate the pancreas to make more insulin), it can offer moderate control of serum glucose levels. In the absence of endogenous insulin—type 1 diabetes, depleted type 2 (in some cases) or latent autoimmune diabetes of adults in late stage—insulin glargine needs the support of fast acting insulin taken with food to reduce the effect of prandially derived glucose. Medical uses[edit] The long-acting insulin class, which includes insulin glargine, do not appear much better than neutral protamine Hagedorn (NPH) insulin but have a significantly greater cost making them, as of 2010, not cost effective.[1] It is unclear if there is a difference in hypoglycemia and not enough data to determine any differences with respect to long term outcomes.[2] Mixing with other insulins[edit] Unlike some other longer-acting insulins, glargine must not be diluted or mixed with other insulin or solution in the same syringe.[3] However, this restriction has been questioned.[4] Adverse effects[edit] Cancer[edit] As of 2012 tentative evidence shows no association between insulin glargine and cancer.[5] Previous studies had raised concerns.[6] Pharmacology[edit] Mechanism of action[edit] Insulin glargine has a substitution of glycine for Continue reading >>

Diabetes Case Study Answers - Nu 320 Pharmacology Diabetes...

Diabetes Case Study Answers - NU 320 Pharmacology Diabetes... NU 320 PharmacologyDiabetes Case StudyYou work I the diabetes mellitus center at a large teaching hospital. The first patient you meet is K.W. a 25-year old Hispanic woman who was just released from the hospital 2 days ago after being diagnosed with type 1 DM.Nine days ago K.W. went to see her physicianafter 1-month history of frequent urination, thirst, severe fatigue, blurred vision, and some burning and tingling in her feet. She attributed those symptoms to working long hours at the computer. Her random glucose level was 410 mg/dL. The next day her laboratory values were as follows: fasting glucose 335 mg/dL, hemoglobin A1C 8.8%, cholesterol 310 mg/dL, triglycerides 300 mg/dL, high density lipoprotein 25 mg/dL, low-density lipoprotein 160 mg/dL and creatinine 0.9 mg/dL. Her body mass index is 37.6, her blood pressure is 160/96. She was admitted to the hospital for control of her glucose levels and the initiation of insulin therapy with carbohydrate counting. After discharge KW has been referred to you for comprehensive education. You are to cover four basic areas: pharmacotherapy, glucose monitoring, medical nutrition therapy and exercise.1.KW was started on sliding scale lispro (Humalog) four times daily and glargine (Lantus) insulin 30 units at bedtime. What is the most significant difference between these two insulin therapies? The difference is their onset, peak, and duration. Lispro is fast-acting insulin with an onset of action within 15 minutes, a peak effect of - 1 hour, and a duration of action of 3-6 hours. Patients using lispro are cautioned not to take it until they sit down to eat or no sooner than 10 minutes before eating. This preview has intentionally blurred sections. Sign up to view the Continue reading >>

Humalog Archives - Goodrx

Heres Why Insulin Is So Expensive And What You Can Do About It The numbers are in: U.S. spending on diabetes drugs increased from $10 billion to $22 billion per year between 2002 and 2012, according to a recent study. And most of that cost was due to skyrocketing prices for one diabetes medication: insulin. Take, for example, Lantus, one of the most popular insulins on the market. Read More Why is Humalog Expensive? And How Can You Save? Humalog (insulinlispro) is a fast-acting insulin used to treat diabetes type one and two. Doctors report low levels of adherence to insulins like Humalog because of its cost. Cash prices for Humalog average around $549 for five kwikpens, and there is no generic alternative for any insulin brand. Humalog generated billions of dollars in global Read More Why Taking Your Medications for These Common Silent Diseases is Important If youve ever been afraid to show up at your doctors office because youve been bad then this post is for YOU! You may think your doctor is pushing medications on you especially if you arent experiencing any symptoms of the condition they are treating you for. However, their reasoning is not without sound medical Read More Mealtime insulins, or fast-acting insulins, are injected before or after each meal to regulate the blood sugar. Type 1 diabetics require mealtime insulin injections as their pancreas does not produce insulin, whereas type 2 diabetics may only require mealtime insulin if they struggle with blood sugar control after meals or are not achieving their target Read More Rapid-Acting Versus Long-Acting Insulin: Whats the Difference? For people who need to take insulin, there are a couple of different typeslong-acting, short-acting, rapid-acting, intermediate-acting, etc. Thats a lot of options! One questi Continue reading >>

Lantus Dosing

Well, I never thought I’d say this, but it’s a great week to be a person with Type 1 diabetes. With all of the bad news surrounding the Type 2 drug Avandia (rosiglitazone), it’s a relief to know I don’t have to worry about it. I recommended you read my colleague Tara’s blog entry (“Type 2 Drug Avandia Linked to Increased Risk of Heart Attacks”) for the full story. That’s one of the first times in my life I’ve referred to someone as a colleague. What can I say? It’s just not a word in my describe-a-friend/coworker vocabulary. While all of the controversy surrounds Avandia, I’m way over in Type 1 land contemplating whether or not to lower my daily dose of Lantus (insulin glargine). I’ve just started a brand new bottle of Lantus and I’ve been taking my normal 15 units in the morning and then eating a rather normal breakfast and lunch, but I’m still going low in the midmorning and early afternoon. This happened Monday after eating Brussels sprouts and whole-wheat pasta for lunch and only taking one unit of rapid-acting NovoLog (insulin aspart) to help out the Lantus. I’ve known for a while that my body is sensitive to insulin, but lately it’s been a little more sensitive than usual. I took 13 units of Lantus yesterday and my blood glucose was 86 mg/dl before lunch. I often wonder how much of an adjustment two units of Lantus is. While I’m very much locked in on an insulin-to-carbohydrate ratio with my NovoLog, it’s a bit tricky to judge how much the longer-lasting insulins affect your blood glucose. Is there a chart for your Lantus dose? I seem to remember something from when I was diagnosed. I wonder what Google will tell me to do. I realize that Lantus doesn’t have a true peak the way some of the other insulins do, but sometimes it su Continue reading >>

Texting Helps Low-Income Diabetes Patients Manage Insulin Dosing

Difference Between Lantus & Humalog

Lantus and Humalog are two different insulin medications that serve a similar purpose. Lantus slowly releases to regulate low levels of insulin while Humalog is a supplemental insulin taken with a meal to control a carbohydrate spike in diabetics. Control Adults with type 2 diabetes and some children with type 1 diabetes require constant dosing of insulin to control sugar levels in the bloodstream. Lantus is intended to give users a 24-hour period of control, whereas Humalog is used to fill in the gaps, and effects diminish in the first hour. Dose Dosing for Lantus and Humalog is personalized to accommodate the blood sugar range of the individual. Both are taken by injection, with Lantus on a once a day schedule and Humalog taken at meals or as needed. Side Effects Humalog and Lantus have similar side effects that may include irritation at or around the injection site, and dangerously low blood sugar levels, also called hypoglycemia. Diabetics should consult with a medical professional if any serious side effects or allergic reactions persist. Absorption The insulin in Lantus is slowly absorbed by the body in a steady stream over a 24-hour period, with the patient feeling little or no reaction. Humalog, on the other hand, is quickly absorbed with results being felt within the first fifteen minutes after taking, depending on doseage and body mass. Timing Lantus is taken once a day, usually in the morning, and left at home. Humalog is taken to supplement the release of insulin coming from a daily Lantus shot. Humalog is taken on a much more flexible, as-needed basis, as dictated by your day's schedule and mealtimes. Continue reading >>

Diabetes Case Study Essay

Nursing B05: Med/Surg Case study # 1, ScenarioY.L. makes an appointment to come to the clinic where you are employed. She has been complaining of chronic fatigue, increased thirst, constant hunger, and frequent urination. She denies any pin, burning, or low-back pain on urination. She tells you she has a vaginal yeast infection that she has treated numerous times with over-the-counter (OTC) medication. She admits to starting smoking since going back to work full time as a clerk in a loan company. She also complains of having difficulty reading numbers and reports making frequent mistakes. She says, By the time I get home, and make supper for my family, them put my child to bed, I am too tired to exercise. She reports her feet show more content Identify the three functions of insulin. * Regulating glucose metabolism * 2. Y.L. was started on Lispro (Humalog) and glargine (Lantus) insulins with carbohydrate counting. What is the most important point to teach the patient about glargine? Glargine cannot be diluted or mixed with any other insulin or solution. 3. Y.L. was on regular insulin in the past when she was pregnant. As the nurse providing her with insulin teaching you want to ensure she understands the difference between regular and lispro. What is the most significant difference between these two insulins? The most significant difference between the regular insulin and the rapid acting insulin is the onset. The onset for rapid-acting or lispro is 10-15 minutes, and for the regular it is -1 hour. 4. Y.L also used to take NPH when pregnant. She is more familiar with it. Provide and explain two advantages of glargine and lispro over NPH and regular. 5. Y.Ls culture prefers foods high in carbohydrates. What is carbohydrate counting, and why would this method work well f Continue reading >>

Humalog Vs. Novolog: Important Differences And More

Humalog and Novolog are two diabetes medications. Humalog is the brand-name version of insulin lispro, and Novolog is the brand-name version of insulin aspart. These drugs both help control blood glucose (sugar) in people with type 1 and type 2 diabetes. Humalog and Novolog are both rapid acting. That means they work more quickly than other types of insulin. There are important distinctions between Humalog and Novolog, however, and the drugs are not directly interchangeable. Check out this comparison so you can work with your doctor to choose a drug that’s right for you. Insulin is injected under your skin fat. It’s the most common type of treatment for type 1 diabetes because it works quickly. It’s also the only type of diabetes medication that’s absorbed into the bloodstream. Humalog and Novolog are both equivalent to the insulin made in your body. Unlike oral diabetes drugs, insulin provides fast relief for changes in your blood sugar. The type of insulin your doctor prescribes depends on how often and how much your blood sugar fluctuates each day. The table below provides quick facts at a glance. Brand name Humalog Novolog What is the generic drug? insulin lispro insulin aspart Is a generic version available? no no What does it treat? type 1 and type 2 diabetes type 1 and type 2 diabetes What form does it come in? solution for injection solution for injection What strengths does it come in? • 3-mL cartridges • 3-mL prefilled KwikPen • 3-mL vials • 10-mL vials • 3-mL FlexPen • 3-mL FlexTouch • 3-mL PenFill cartridges • 10-mL vials What is the typical length of treatment? long-term long-term How do I store it? Refrigerate at 36° to 46°F (2° to 8°C). Do not freeze the drug. Refrigerate at 36° to 46°F (2° to 8°C). Do not freeze the drug. Continue reading >>